Physician profile
Edin Basic
NPI 1124206685
$9,633.46
in general payments reported to CMS, 2019-2025
33 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $538 · 2021: $939 · 2022: $1,697 · 2023: $1,951 · 2024: $2,677 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,536 · Consulting Fee: $375 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,536.18 |
| Consulting Fee | $375.00 |
| Education | $228.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $995.33 | 2021-2025 | Tavneos, Krystexxa, Repatha |
| Calliditas Therapeutics US INC. | $762.27 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $732.70 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $718.95 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $704.11 | 2022-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $703.71 | 2024-2025 | Filspari |
| Astrazeneca Pharmaceuticals Lp | $669.42 | 2020-2025 | Farxiga, Lokelma, Xigduo |
| Horizon Therapeutics Plc | $625.37 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $597.96 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $545.74 | 2019-2025 | Jynarque, Voyxact |
| Alexion Pharmaceuticals, INC. | $291.17 | 2019-2023 | Ultomiris |
| Aurinia Pharma U.S., INC. | $279.09 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.86 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $254.01 | 2021-2024 | Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $211.52 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $153.04 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $142.37 | 2020-2024 | Rayaldee |
| Ardelyx, INC. | $137.70 | 2023-2025 | Ibsrela |
| Cormedix INC. | $129.20 | 2024-2025 | Defencath, Defencath |
| Novo Nordisk INC | $121.93 | 2024-2025 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $91.75 | 2020-2023 | Injectafer |
| Lilly USA, LLC | $74.47 | 2024-2025 | Jardiance |
| Genzyme Corporation | $68.14 | 2021-2023 | |
| Bard Peripheral Vascular, INC. | $62.63 | 2022 | |
| Boston Scientific Corporation | $54.14 | 2021 | |
| Xeris Pharmaceuticals, INC. | $46.72 | 2024-2025 | Keveyis |
| Shire North American Group INC | $46.18 | 2019 | |
| Philips North America LLC | $44.14 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $39.84 | 2019 | |
| Ascendis Pharma Endocrinology INC | $21.18 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $18.96 | 2020 | |
| Medtronic, INC. | $14.58 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edin Basic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.